Treatment with Obecabtagene Autoleucel Results in Durable Response Among Adults with Relapsed or Refractory B-Cell ALL By Ogkologos - December 12, 2024 800 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the FELIX study Source RELATED ARTICLESMORE FROM AUTHOR New Targeted Therapy Shows Promising Early Results in Advanced Pancreatic Cancer FDA Approves Pivekimab Sunirine-pvzy for Blastic Plasmacytoid Dendritic Cell Neoplasm, an Ultra-Rare Haematologic Malignancy Ivonescimab Plus Chemotherapy Improves OS Compared with Tislelizumab Plus Chemotherapy in Previously Untreated Patients with Advanced Squamous NSCLC MOST POPULAR Osimertinib After Definitive Chemoradiotherapy Prolongs PFS in Patients with Unresectable Stage... June 6, 2024 Hairstylist Creates Custom Wigs & Donates Them To Cancer Patients October 23, 2021 Cancer Research UK report highlights stark cancer inequalities across Scotland November 28, 2022 Investing in volunteers since 2002: The tale of time July 11, 2022 Load more HOT NEWS Alternatives for Outdoor Foods COVID-19: “It could take months to build research up again” EMA Recommends Granting a Marketing Authorisation for Inavolisib Metastatic Breast Cancer: New ESMO Guideline With Evidence-Based Recommendations [ESMO Press...
